To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study

Eur J Clin Pharmacol. 2022 Jan;78(1):43-51. doi: 10.1007/s00228-021-03146-5. Epub 2021 Aug 28.

Abstract

Purpose: The purpose of this paper is to study the correlation between demographic and clinical factors and warfarin dose of patients in Chinese Han population taking warfarin and study gene polymorphisms impact of related gene loci (CYP2C9*3, VKORC1-1639G > A) on warfarin doses, to establish a model to predict initial standard dose and maintenance dose based on CYP2C9*3, VKORC1-1639G > A genotype.

Methods: The study collects the data of patients in our hospital and other subcenters which incorporates 2160 patients to establish the initial dose model and 1698 patients for the stable dose model, and sequences 26 multigene sites in 451 patients. Based on the patient's dosage, clinical data, and demographic characteristics, the genetic and non-genetic effects on the initial dose and stable dose of warfarin are calculated by using statistical methods, and the prediction model of initial standard dose and maintenance dose can be established via multiple linear regression.

Results: The initial dose of warfarin (mg/day) was calculated as (1.346 + 0.350 × (VKORC1-1639G > A) - 0.273 × (CYP2C9*3) + 0.245 × (body surface area) - 0.003 × (age) - 0.036 × (amine-iodine) + 0.021 × (sex))2. This model incorporated seven factors and explained 55.3% of the individualization differences of the warfarin drug dose. The maintenance dose of warfarin (mg/day) was calculated as (1.336 + 0.299 × (VKORC1-1639G > A) + 0.480 × (body surface area) - 0.214 × (CYP2C9*3) - 0.074 × (amine-iodine) - 0.003 × (age) - 0.077 × (statins) - 0.002 × (height))2. This model incorporated six factors and explained 42.4% of the individualization differences in the warfarin drug dose.

Conclusion: The genetic and non-genetic factors affecting warfarin dose in Chinese Han population were studied systematically in this study. The pharmacogenomic dose prediction model constructed in this study can predict anticoagulant efficacy of warfarin and has potential application value in clinical practice.

Keywords: CYP2C9; Gene polymorphism; Model; VKORC1; Warfarin.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Anticoagulants / administration & dosage*
  • Anticoagulants / pharmacokinetics*
  • Asian People
  • Body Surface Area
  • China
  • Comorbidity
  • Cytochrome P-450 CYP2C9 / genetics*
  • Dose-Response Relationship, Drug
  • Ethnicity
  • Female
  • Genotype
  • Health Behavior
  • Humans
  • International Normalized Ratio
  • Male
  • Middle Aged
  • Pharmacogenetics
  • Pharmacogenomic Variants
  • Polymorphism, Genetic
  • Sex Factors
  • Sociodemographic Factors
  • Warfarin / administration & dosage*
  • Warfarin / pharmacokinetics*

Substances

  • Anticoagulants
  • Warfarin
  • Cytochrome P-450 CYP2C9